Yusuke Tsuda

Yusuke Tsuda

Auto-generated profile, based on publicly available information

Yusuke Tsuda

Oncology Service, The Royal Orthopaedic Hospital NHS Foundation Trust, Birmingham, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Archives of orthopaedic and trauma surgery
Verified
Journal Article
Closed access
PDF file
YTYusuke Tsuda
Yusuke Tsuda
HYHideo Yasunaga
Hideo Yasunaga
HHHiromasa Horiguchi
Hiromasa Horiguchi
SOSumito Ogawa
Sumito Ogawa
HKHirotaka Kawano
Hirotaka Kawano
STSakae Tanaka
Sakae Tanaka

5 October 2015 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
YTYusuke Tsuda
Yusuke Tsuda
HYHideo Yasunaga
Hideo Yasunaga
HHHiromasa Horiguchi
Hiromasa Horiguchi
KFKiyohide Fushimi
Kiyohide Fushimi
HKHirotaka Kawano
Hirotaka Kawano
STSakae Tanaka
Sakae Tanaka

8 November 2019 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
YTYusuke Tsuda
Yusuke Tsuda
KTKim Tsoi
Kim Tsoi
JSJonathan Daniel Stevenson
Jonathan Daniel Stevenson
TFTomohiro Fujiwara
Tomohiro Fujiwara
RTRoger Tillman
Roger Tillman
AAAdesegun Abudu
Adesegun Abudu
Background: Extendable endoprostheses are used to reconstruct segmental defects following resection of bone sarcomas in skeletally immature patients. However, there remains a paucity of studies with regard to long-term outcomes. Methods: We retrospectively reviewed 124 skeletally immature children who underwent an extendable endoprosthetic replacement and survived more than 10 years after the surgical procedures. Anatomical sites included the distal part of the femur (n = 66), the proximal part of the femur (n = 13), the proximal part of the tibia (n = 29), and the proximal part of the humerus (n = 16). Complications and implant survival were classified according to the modified Henderson criteria. Results: The mean follow-up was 24 years (range, 10 to 36 years). The mean age at the time of the extendable endoprosthetic replacement was 9 years (range, 2 to 16 years). All patients had reached skeletal maturity at the last follow-up. The 10-year endoprosthetic failure-free survival rate was 28%. A total of 243 complications occurred in 90% of patients; these complications were most frequently related to soft-tissue problems (27% of complications). The incidence of and cumulative survival with respect to each failure mode varied between anatomical sites. Soft-tissue failures occurred most frequently in the proximal part of the femur (77%; p = 0.003), and the distal part of the femur was the most frequent site of aseptic loosening (52%; p = 0.014) and structural failure (55%; p = 0.001). Excluding lengthening procedures, 105 patients (85%) underwent an additional surgical procedure, with a mean of 2.7 surgical procedures per patient (range, 0 to 7 surgical procedures per patient). The mean limb-length discrepancy at the final follow-up was 1 cm (range, 0 to 9 cm). Limb salvage was achieved in 113 patients (91%). The mean Musculoskeletal Tumor Society functional score (the percentage of a total score of 30 points) was 82% (range, 40% to 100%) in 115 patients with available data at the last follow-up. Conclusions: Extendable endoprostheses are associated with a high complication rate and a need for additional surgical procedures over time. Despite this, successful limb salvage with reasonable function and small limb-length discrepancy is achievable in the long term. Our study provides benchmark data for individual anatomical sites for further improvements of outcomes. Level of Evidence: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.

31 May 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YTYusuke Tsuda
Yusuke Tsuda
KOKOICHI OGURA
KOICHI OGURA
YSYusuke Shinoda
Yusuke Shinoda
HKHiroshi Kobayashi
Hiroshi Kobayashi
STSakae Tanaka
Sakae Tanaka
AKAkira Kawai
Akira Kawai
Few reports have described clinical features, prognosis and prognostic factors of osteosarcoma patients according to age. Using the Bone and Soft Tissue Tumor Registry in Japan, we identified 1043 osteosarcoma patients including 760 who were younger than 40 years, 173 aged between 41 and 64 years, and 110 patients older than 65 years. We extracted data on patient demographics and prognosis. Prognostic factors for patients older than 65 years or other age groups were analyzed. Patients older than 65 years showed a significantly higher proportion of tumors arising in the trunk and with metastasis at diagnosis, and their 5-year disease-specific survival (DSS) rate was 32.7%. Multivariate analysis showed that the presence of metastasis at diagnosis [hazard ratio (HR): 3.04; 95% confidence interval (CI), 1.63–5.69; P < 0.001] and tumors > 16 cm in size (HR: 2.84 compared with < 8 cm; 95% CI, 1.16–6.97; P = 0.023) were significantly associated with worse DSS. The 5-year DSS was 39.1% in 80 patients older than 65 years without metastasis at diagnosis. Methotrexate was used in only 5.0% of these patients. Adjuvant chemotherapy was not significantly associated with better DSS (P = 0.323) in this generation and aged between 41 and 64 years (P = 0.566), although adjuvant chemotherapy yielded significantly better survival in patients younger than 40 years (P < 0.001). Analysis of this cohort of osteosarcoma patients revealed some unique clinical, therapeutic and prognostic features according to age groups in the largest cohort. Adjuvant chemotherapy was not associated with a better DSS in the group of patients aged between 41 and 64 years or older than 65 years.

1 October 2019 in The Bone & Joint Journal
Verified
Journal Article
Closed access
YTYusuke Tsuda
Yusuke Tsuda
JGJonathan J. Gregory
Jonathan J. Gregory
TFTomohiro Fujiwara
Tomohiro Fujiwara
SASeggy Abudu
Seggy Abudu
Aims: The aim of this study was to report the outcomes of patients who underwent definitive surgery for secondary chondrosarcomas arising from osteochondromas. Patients and Methods: A total of 51 patients with secondary chondrosarcomas occurring from osteochondromas were reviewed. Median age was 36 years (interquartile range (IQR) 15 to 82). Median follow-up was 6.9 years (IQR 2.8 to 10.6). The pelvis was the most commonly affected site (59%). Histological grades were grade I in 35 (69%), grade II in 13 (25%), and grade III in three patients (6%). Results: Preoperative biopsy histology correctly predicted the final histological grade in 27% of patients. The ten-year disease-specific survival (DSS) for all patients was 89.4%. Local recurrence occurred in 15 patients (29%), more commonly in pelvic tumours (37%) compared with limb tumours (19%). Four patients with pelvic tumours died from progression of local recurrence. No patient with limb tumours died of disease. Wide/radical margin was associated with improved local recurrence-free survival (p = 0.032) and local recurrence was associated with worse DSS (p = 0.005). Conclusion: We recommend that a secondary chondrosarcoma arising from osteochondroma of the pelvis is resected with wide/radical resection margins. The balance between the morbidity of surgery and risk of local recurrence needs to be considered in patients with limb secondary chondrosarcomas. Cite this article: Bone Joint J 2019;101-B:1313–1320

20 August 2019 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
YTYusuke Tsuda
Yusuke Tsuda
SEScott Evans
Scott Evans
JSJonathan D Stevenson
Jonathan D Stevenson
MPMichael Parry
Michael Parry
TFTomohiro Fujiwara
Tomohiro Fujiwara
LJLee Jeys
Lee Jeys
Background: We attempted to resect peripheral chondrosarcoma of the pelvis with clear margins. Because of the proximity of vessels or organs, there is still concern that narrow surgical margins may have an adverse effect on disease outcomes. Although current guidelines recommend resection of histologic Grade II or Grade III chondrosarcomas with a “wide” margin, there are no specific recommendations for the adequate width of a surgical margin. Questions/purposes: (1) What is the disease-specific and local recurrence-free survival of patients with peripheral chondrosarcoma of the pelvis treated with resection or amputation? (2) Is the width of a surgical margin associated with the outcome of disease in patients with peripheral chondrosarcoma of the pelvis? (3) Does the histologic grade as determined with a preoperative biopsy correlate with the final grade after resection? (4) What are surgical complications in these patients? Methods: We retrospectively reviewed records from three international collaborating hospitals. Between 1983 and 2017, we resected 262 pelvic chondrosarcomas of all types. After reviewing the pathologic reports of these patients, we included 52 patients with peripheral chondrosarcomas of the pelvis who had an osteochondroma-like lesion at the base of the tumor and a cartilage cap with malignant cells in resected specimens. To be eligible for this study, a patient had to have a minimum of 1 year of follow-up. Two patients were excluded because they had less than 1 year of follow-up, leaving 50 patients for inclusion in this study. The median follow-up duration was 7.0 years (interquartile range 2.1-10 years). The median age was 37 years (IQR 29-54 years). The ilium was the most frequently affected bone (in 36 of 50 patients; 72%). The histologic status of the surgical margin was defined as microscopically positive (0 mm), negative < 1 mm, or negative ≥ 1 mm. Thirteen of the 50 patients (26%) had local recurrence. Seven of 34 patients had Grade I tumors, five of 13 had Grade II tumors, and one of three had a Grade III tumor. Nine of 16 patients had multiple local recurrences. Two patients with Grade I tumors and two with Grade II tumors died because of pressure effects caused by local recurrence. Results: The 10-year disease-specific and local recurrence-free survival rates were 90% (95% confidence interval, 70-97) and 69% (95% CI, 52-81), respectively. A surgical margin ≥ 1 mm (n = 16) was associated with a better local recurrence-free survival rate than a surgical margin < 1 mm (n = 17) or 0 mm (n = 11) (10-year local recurrence-free survival: resection margin ≥ 1 mm = 100% versus < 1 mm = 52% [95% CI, 31 to 70]; p = 0.008). No patients with a surgical margin ≥ 1 mm had local recurrence, metastasis, or disease-related death, irrespective of tumor grade. Patients with local recurrence (n = 13) showed worse disease-specific survival than those without local recurrence (n = 37) (10-year disease-specific survival: local recurrence [+] = 59% [95% CI, 16 to 86] versus local recurrence [-] = 100%; p=0.001]). The preoperative biopsy results correctly determined the tumor grade in 15 of 41 patients (37%). The most frequent complication after surgery was local recurrence (13 of 50 patients, 26%). Deep infection was the most frequent nononcologic complication (four patients). Conclusions: We found a high local recurrence rate after surgical treatment of a peripheral pelvic chondrosarcoma, which was related to the width of the surgical margin. These local recurrences led to inoperable recurrent tumors and death. The tumor grade as determined by preoperative biopsy was inaccurate in 2/3 of patients compared with the final histologic assessment. Therefore, we believe every attempt should be made to achieve a negative margin during the initial resection to lessen the likelihood of local recurrence of peripheral chondrosarcoma of the pelvis of all grades. A margin of 1 mm or more appeared to be sufficient in these patients. Level of Evidence: Level III, therapeutic study.